Q2 FY2026 EarningsQ2 FY26 results beat consensus across most key metrics despite regulatory headwinds from the Inflation Reduction Act (IRA). Revenue reached $351.8M vs. $340.5M expected, while GAAP EPS of $0.34 significantly outperformed the $0.225 mean estimate. The variance was primarily driven by a $8.5M one-time legal settlement related to payor reimbursement. While organic revenue fell due to IRA pricing adjustments, resident growth (+7.7% YoY) and prescription volume (+8.6% YoY) provided a strong operational offset.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Guardian Pharmacy Services(GRDN) the Revenue is 351.77 M (+2.16%), Beat estimate;the EBIT is 20.64 M (+64.1%), Beat estimate;the EPS is 0.34 (+142.9%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.35B2.16%
0.34B1.13%
+0.01B3.29%
EBITExceed expectations
0.02B64.10%
0.02B57.01%
+0.00B7.09%
EPSExceed expectations
0.34142.86%
0.22560.71%
+0.115082.15%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf